肠道菌群
胰岛素抵抗
代谢物
生物化学
生物
胆汁酸
脂质代谢
胰岛素
转录因子
脂肪肝
药理学
胰岛素受体
化学
蛋白激酶B
脂肪酸
碳水化合物代谢
新陈代谢
油酸
代谢综合征
代谢途径
代谢紊乱
细胞因子
促炎细胞因子
内分泌学
PI3K/AKT/mTOR通路
2型糖尿病
代谢组学
脂肪酸代谢
细菌
短链脂肪酸
作者
Mengran Qi,Feini Qin,王若瑄,Yanni Zhang,Xuanfeng YUE
出处
期刊:Food & Function
[Royal Society of Chemistry]
日期:2026-09-21
卷期号:17 (18): 8244-8266
摘要
oleic acid (OA)-induced HepG2 cells, as well as 16S rRNA gene sequencing and untargeted metabolomics of cecal contents. EC dose-dependently improved metabolic disturbances in HFD-fed mice and OA-induced HepG2 cells, as evidenced by reduced body weight gain, liver index, serum transaminases, and hepatic triglyceride/cholesterol levels, alongside enhanced glucose tolerance and insulin sensitivity. Mechanistically, EC alleviated insulin resistance and lipid accumulation by inhibiting the aberrant phosphorylation of JNK and IRS-1, thereby restoring AKT activation, and concurrently suppressing the expression of the lipogenic transcription factor SREBP-1c and the inflammatory cytokine TNF-α. In parallel, EC remodeled the gut microbiota by decreasing the Firmicutes/Bacteroidota ratio, specifically enriching the beneficial genus Akkermansia, and modulating cecal metabolite profiles, particularly affecting bile acid, fatty acid, and amino acid metabolism pathways. These findings suggest that EC ameliorates NAFLD potentially through dual direct (hepatic insulin signaling) and indirect (gut-liver axis) mechanisms, highlighting its potential as a promising natural candidate for NAFLD therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI